By the time Genentech began recruiting Doudna in late 2008, the company was worth close to $100 billion. Her former colleague, who was now working on genetically engineering cancer drugs at Genentech, told her that he was loving his new role. His research was much more focused than when he was an academic, and he was working directly on problems that were going to lead to new therapeutics.
